PHOTOCURE ASA (PHO.OL) Fundamental Analysis & Valuation

OSL:PHO • NO0010000045

Current stock price

63.7 NOK
-0.6 (-0.93%)
Last:

This PHO.OL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. PHO.OL Profitability Analysis

1.1 Basic Checks

  • In the past year PHO has reported negative net income.
  • PHO had a positive operating cash flow in the past year.
  • PHO had negative earnings in 4 of the past 5 years.
  • Of the past 5 years PHO 4 years had a positive operating cash flow.
PHO.OL Yearly Net Income VS EBIT VS OCF VS FCFPHO.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M -100M -150M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -0.21%, PHO is doing worse than 62.75% of the companies in the same industry.
  • PHO has a Return On Equity of -0.31%. This is in the lower half of the industry: PHO underperforms 62.75% of its industry peers.
Industry RankSector Rank
ROA -0.21%
ROE -0.31%
ROIC N/A
ROA(3y)-0.18%
ROA(5y)-2.89%
ROE(3y)-0.26%
ROE(5y)-4.49%
ROIC(3y)N/A
ROIC(5y)N/A
PHO.OL Yearly ROA, ROE, ROICPHO.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 -20

1.3 Margins

  • PHO's Gross Margin of 92.11% is amongst the best of the industry. PHO outperforms 96.08% of its industry peers.
  • PHO's Gross Margin has been stable in the last couple of years.
  • The Profit Margin and Operating Margin are not available for PHO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 92.12%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.75%
GM growth 5Y-0.14%
PHO.OL Yearly Profit, Operating, Gross MarginsPHO.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. PHO.OL Health Analysis

2.1 Basic Checks

  • PHO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • PHO has less shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, PHO has less shares outstanding
  • The debt/assets ratio for PHO is higher compared to a year ago.
PHO.OL Yearly Shares OutstandingPHO.OL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M
PHO.OL Yearly Total Debt VS Total AssetsPHO.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • An Altman-Z score of 5.87 indicates that PHO is not in any danger for bankruptcy at the moment.
  • PHO has a Altman-Z score of 5.87. This is amongst the best in the industry. PHO outperforms 84.31% of its industry peers.
  • The Debt to FCF ratio of PHO is 19.05, which is on the high side as it means it would take PHO, 19.05 years of fcf income to pay off all of its debts.
  • PHO's Debt to FCF ratio of 19.05 is on the low side compared to the rest of the industry. PHO is outperformed by 68.63% of its industry peers.
  • A Debt/Equity ratio of 0.21 indicates that PHO is not too dependend on debt financing.
  • PHO's Debt to Equity ratio of 0.21 is fine compared to the rest of the industry. PHO outperforms 70.59% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF 19.05
Altman-Z 5.87
ROIC/WACCN/A
WACC8.6%
PHO.OL Yearly LT Debt VS Equity VS FCFPHO.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M

2.3 Liquidity

  • A Current Ratio of 3.64 indicates that PHO has no problem at all paying its short term obligations.
  • PHO has a Current ratio of 3.64. This is amongst the best in the industry. PHO outperforms 92.16% of its industry peers.
  • A Quick Ratio of 3.22 indicates that PHO has no problem at all paying its short term obligations.
  • PHO's Quick ratio of 3.22 is amongst the best of the industry. PHO outperforms 92.16% of its industry peers.
Industry RankSector Rank
Current Ratio 3.64
Quick Ratio 3.22
PHO.OL Yearly Current Assets VS Current LiabilitesPHO.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. PHO.OL Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 54.03% over the past year.
  • The Revenue has been growing slightly by 1.37% in the past year.
  • PHO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 15.74% yearly.
EPS 1Y (TTM)54.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-88.32%
Revenue 1Y (TTM)1.37%
Revenue growth 3Y10.65%
Revenue growth 5Y15.74%
Sales Q2Q%5.45%

3.2 Future

  • The Earnings Per Share is expected to decrease by -8.63% on average over the next years.
  • PHO is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 16.26% yearly.
EPS Next Y-74.23%
EPS Next 2Y25.27%
EPS Next 3Y-8.63%
EPS Next 5YN/A
Revenue Next Year15.11%
Revenue Next 2Y12.58%
Revenue Next 3Y13.51%
Revenue Next 5Y16.26%

3.3 Evolution

  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
PHO.OL Yearly Revenue VS EstimatesPHO.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
PHO.OL Yearly EPS VS EstimatesPHO.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 1 -1 2 -2

More info and screens

Find the best growth stocksShow best growing peers

0

4. PHO.OL Valuation Analysis

4.1 Price/Earnings Ratio

  • PHO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • With a Price/Forward Earnings ratio of 168.18, PHO can be considered very expensive at the moment.
  • PHO's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. PHO is more expensive than 68.63% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 22.19. PHO is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 168.18
PHO.OL Price Earnings VS Forward Price EarningsPHO.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -200 -400 -600 -800 -1K

4.2 Price Multiples

  • PHO's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. PHO is more expensive than 66.67% of the companies in the same industry.
  • PHO's Price/Free Cash Flow ratio is a bit more expensive when compared to the industry. PHO is more expensive than 68.63% of the companies in the same industry.
Industry RankSector Rank
P/FCF 328.87
EV/EBITDA 55.87
PHO.OL Per share dataPHO.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • A cheap valuation may be justified as PHO's earnings are expected to decrease with -8.63% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.27%
EPS Next 3Y-8.63%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PHO.OL Dividend Analysis

5.1 Amount

  • PHO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PHO.OL Fundamentals: All Metrics, Ratios and Statistics

PHOTOCURE ASA

OSL:PHO (3/27/2026, 7:00:00 PM)

63.7

-0.6 (-0.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-18
Earnings (Next)05-07
Inst Owners41.67%
Inst Owner ChangeN/A
Ins Owners2.81%
Ins Owner ChangeN/A
Market Cap1.73B
Revenue(TTM)532.58M
Net Income(TTM)-1.52M
Analysts82.86
Price Target81.6 (28.1%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.02%
Min Revenue beat(2)-2.51%
Max Revenue beat(2)0.47%
Revenue beat(4)2
Avg Revenue beat(4)-1.3%
Min Revenue beat(4)-5.24%
Max Revenue beat(4)2.07%
Revenue beat(8)4
Avg Revenue beat(8)-1.81%
Revenue beat(12)6
Avg Revenue beat(12)-2.3%
Revenue beat(16)8
Avg Revenue beat(16)-2.79%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-61.6%
EPS NY rev (3m)-61.6%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)2.95%
Revenue NY rev (3m)1.82%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 168.18
P/S 3.24
P/FCF 328.87
P/OCF 66.55
P/B 3.57
P/tB 6.62
EV/EBITDA 55.87
EPS(TTM)-0.06
EYN/A
EPS(NY)0.38
Fwd EY0.59%
FCF(TTM)0.19
FCFY0.3%
OCF(TTM)0.96
OCFY1.5%
SpS19.64
BVpS17.86
TBVpS9.63
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -0.21%
ROE -0.31%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 92.12%
FCFM 0.99%
ROA(3y)-0.18%
ROA(5y)-2.89%
ROE(3y)-0.26%
ROE(5y)-4.49%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.75%
GM growth 5Y-0.14%
F-Score4
Asset Turnover0.75
Health
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF 19.05
Debt/EBITDA 3.48
Cap/Depr 70.25%
Cap/Sales 3.89%
Interest Coverage N/A
Cash Conversion 90.36%
Profit Quality N/A
Current Ratio 3.64
Quick Ratio 3.22
Altman-Z 5.87
F-Score4
WACC8.6%
ROIC/WACCN/A
Cap/Depr(3y)51.48%
Cap/Depr(5y)36.92%
Cap/Sales(3y)2.84%
Cap/Sales(5y)2.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)54.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-88.32%
EPS Next Y-74.23%
EPS Next 2Y25.27%
EPS Next 3Y-8.63%
EPS Next 5YN/A
Revenue 1Y (TTM)1.37%
Revenue growth 3Y10.65%
Revenue growth 5Y15.74%
Sales Q2Q%5.45%
Revenue Next Year15.11%
Revenue Next 2Y12.58%
Revenue Next 3Y13.51%
Revenue Next 5Y16.26%
EBIT growth 1Y-103.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year48.59%
EBIT Next 3Y24.55%
EBIT Next 5YN/A
FCF growth 1Y-91.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-66.18%
OCF growth 3YN/A
OCF growth 5Y10.74%

PHOTOCURE ASA / PHO.OL Fundamental Analysis FAQ

What is the fundamental rating for PHO stock?

ChartMill assigns a fundamental rating of 3 / 10 to PHO.OL.


What is the valuation status of PHOTOCURE ASA (PHO.OL) stock?

ChartMill assigns a valuation rating of 0 / 10 to PHOTOCURE ASA (PHO.OL). This can be considered as Overvalued.


Can you provide the profitability details for PHOTOCURE ASA?

PHOTOCURE ASA (PHO.OL) has a profitability rating of 2 / 10.


What is the financial health of PHOTOCURE ASA (PHO.OL) stock?

The financial health rating of PHOTOCURE ASA (PHO.OL) is 7 / 10.


Can you provide the expected EPS growth for PHO stock?

The Earnings per Share (EPS) of PHOTOCURE ASA (PHO.OL) is expected to decline by -74.23% in the next year.